Cadrenal Therapeutics (CVKD) Net Equity Issued and Repurchased (2023 - 2026)

Cadrenal Therapeutics has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at -$63970.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 25.04% year-over-year to -$63970.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 84.55% YoY) and the FY2025 annual result came in at $4.9 million, down 5.48% from the prior year.
• Net Equity Issued and Repurchased retreated to -$63970.0 in Q1 2026 per CVKD's latest filing, from $846108.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $5.4 million in Q1 2023 and troughed at -$85335.0 in Q1 2025.
• A 4-year average of $1.7 million and a median of $757044.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased tumbled 75.88% in 2025, then gained 25.04% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $5.4 million in 2023, then plunged by 35.14% to $3.5 million in 2024, then sank by 75.88% to $846108.0 in 2025, then slumped by 107.56% to -$63970.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$63970.0, $846108.0, and $667980.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.